Cloud Banner

Medical Devices

Image

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market - Industry Trends and Forecast to 2030

  • Medical Devices
  • Upcoming Report
  • May 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market - Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - 17.169999999999998% Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 1173.84 Million
Diagram Market Size (Forecast Year) USD 4170.06 Million
Diagram CAGR 17.169999999999998%

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In Vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Application, Non-Cancer Applications, Non-Invasive Prenatal Testing (NIPT), Organ Transplantation, Infectious Disease Testing), Clinical Application (Early Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Prognosis and Recurrence Monitoring), Sample Type, (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), Product (Kits & Reagents, Blood Collection Tubes, Devices or System), Specimen (Blood, Bone Marrow, Other Body Fluids), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories) - Industry Trends and Forecast to 2023 to 2030.

Circulating Tumor Cells (CTC) Liquid Biopsy Market Analysis and Size

The essential factors contributing to the growth of the circulating tumor cells (CTC) liquid biopsy market in the forecast period of 2023-2030 include the growing demand of circulating tumor cells (CTC) liquid biopsy because of their effectiveness, increasing prevalence of cancer due to various genetic disorders, increasing alcohol consumption, and lifestyle changes. Along with this, the rising utilization of CTC for patient screening for metastasis and preclinical studies of emerging cancer drugs is contributing in the market’s growth. In addition, introduction of nanotechnology for improving the sensitivity and efficiency of CTC isolation and detection, widespread adoption of CTC-based liquid biopsy for rapid recovery and the rising demand for minimally invasive (MI) diagnostic procedures are significantly boosting the market’s growth.

Data Bridge Market Research analyses that the circulating tumor cells (CTC) liquid biopsy market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In Vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Application, Non-Cancer Applications, Non-Invasive Prenatal Testing (NIPT), Organ Transplantation, Infectious Disease Testing), Clinical Application (Early Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Prognosis and Recurrence Monitoring), Sample Type, (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), Product (Kits & Reagents, Blood Collection Tubes, Devices or System), Specimen (Blood, Bone Marrow, Other Body Fluids), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

QIAGEN (Germany), Bio-Techne (U.S.), Precision Medical Group, LLC. (U.S.), Aviva Systems Biological Corporation (U.S.), Biocept, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), Greiner Bio-One International GmbH (Austria) , Ikonisys  (U.S.), Miltenyi Biotec (Germany), IVDiagnostics (U.S.), BioFluidica (U.S.), Canopus Medical (Sweden), Biolidics Limited (Singapore), Creativ MicroTech, Inc. (U.S.), LungLife AI, Inc. (U.S.), Epic Sciences (U.S.), Rarecells Diagnostics (France), ScreenCell (France), Menarini Silicon Biosystems (U.S.).

Market Opportunities

  • Growth opportunities in growing countries
  • Increasing R&D associated with liquid biopsy

Market Definition

The liquid biopsy is a type of non-invasive blood test which identifies circulating tumor cells and tumor DNA fragments which are released in the blood by primary tumors and metastatic sites. It is an alternative to surgical biopsy procedure, and it allows surgeon to detect cancer at a very early stage. The circulating tumor cells function as a seed of metastases. The patients who have developed solid tumors it is found in them. The detection and quantification of tumor cells in the blood of cancer patients is allowed by the testing of circulating tumor cells. There are various types of biological phenotypes of circulating tumor cells (CTCs) such as stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity and due to which, a phase of isolation-enrichment is required in their detection. 

Global Circulating Tumor Cells (CTC) Liquid Biopsy Dynamics

Drivers

  • Rising prevalence of cancer

The rising prevalence of different types of cancer is boosting the market’s growth. The increasing number of cancer cases across the world is fuelling the demand of liquid biopsy. Breast cancer was the most common cancer 2020 with 2.26 million cases and further lung cancer with 2.21 million cases. The rising prevalence of cancer can be reduced through early detection of cancer and appropriate treatment. Circulating cancer cells are suitable for developing preclinical models, particularly 3D organoid cultures, for use in drug screening, disease modelling, genome editing, and organoid biobanks, thus significantly driving the market’s growth.

  • Awareness initiatives by global health organizations and government

The governments in various countries and global health organizations are spreading awareness about cancer and other growing diseases. National Cancer Control program of WHO, is a public health program aiming to reduce the growing number of cancer deaths and improve the life of cancer patients. Furthermore, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), initiated by the US Centers for Diseases and Prevention (CDC) in 1991, provides breast cancer screening and diagnosis for uninsured and low-income patients in the US every year. The rising awareness in people about the effects and necessity to cure the diseases is increasing the liquid biopsy tests and treatments further driving the market’s growth.

Opportunities

  • Growth opportunities in emerging countries

The developing countries such as India, Brazil, Turkey, Russia, South Africa, China, South Korea are offering major growth opportunities for liquid biopsy market. The major factors owing to the growth of liquid biopsy market in developing economies include improving healthcare infrastructure, higher cancer prevalence, large patient population, increasing disposable income, and growing medical tourism. Thus, there are number of opportunities for the market’s growth.

  • Increasing R&D associated with liquid biopsy

The new research and development in liquid biopsies have revolutionized several related technologies, clinical oncology, devising personalized therapeutic regimens, offering easy tumor sampling, continuous monitoring by repeated sampling, and screening for therapeutic resistance. The increasing research and development is further increasing the demand of liquid biopsy which further increases the market’s growth.

Restraints/Challenges

  • The lower sensitivity of certain liquid biopsies

In liquid biopsies certain procedures are technically challenging such as Detecting ctDNA because the levels of ctDNA of any given cancer mutation can be very low in the plasma of a cancer patient, after treatment or surgery. ctDNA is not applicable to all cancers, some tumor types are bad ctDNA shedders such as gliomas and sarcomas, and acts as an hurdle for ctDNA profiling. The reason for low ctDNA levels is not clear but is considered to be associated with tumor vascularity, location or the blood-brain barrier. Thus, the lower sensitivity of certain liquid biopsies is a major challenge for the market’s growth.

  •  Unclear reimbursement scenario

Limited reimbursement (non-coverage for panel-based tests) restricts the growth of liquid biopsy testing. The guidelines of NCD proved favorable for approval of Foundation One’s genomic profiling assay, but there are possibilities that it can work against other companies developing NGS-panel tests under LDT scenario. Multigene NGS tests have not secured FDA approval or reimbursement coverage, it is up to Medicare Administrative Contractors (MACs) to approve coverage when a company seeks a local coverage determination (LCD) if multigene NGS tests have not secured FDA approval or reimbursement coverage. These unclear reimbursement scenarios will be creating an unfavorable situation for liquid biopsy market’s growth.

This circulating tumor cells (CTC) liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the circulating tumor cells (CTC) liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In November 2021, Myriad Genetics, Inc. announced that it has presented the data at San Antonio Breast Cancer Symposium and highlighted the value of genetic testing in breast cancer treatment. This will help Myriad Genetics, Inc. to advance the launch of novel product in the market. This advancement will further fuel the growth of liquid biopsy market’s growth.
  • In February 2021, Menarini Silicon Biosystems announced the launch of CellMag product line for manual enrichment and staining of circulating tumor cells. This has helped Menarini Silicon Biosystems to increase its product line and will significantly boosts the market’s growth.

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope

The circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of technology, application, clinical application, sample type, product, specimen and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

  • CTC Detection Methods
  • CTC Enrichment Methods
  • Ex Vivo Positive Selection
  • Molecular (RNA)-Based Technologies
  • Functional In Vitro Cell Invasion Assay
  • Xenotransplantation Models
  • Microchips
  • Single Spiral Microchannel
  • Negative Selection & Immunocytochemical Technologies

 Application

  • Cancer Application
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Other Cancers
  • Non-Cancer Applications
  • Non-Invasive Prenatal Testing (NIPT)
  • Organ Transplantation
  • Infectious Disease Testing

Clinical Application

  • Early Cancer Screening
  • Diagnosis
  • Therapy Selection
  • Treatment Monitoring
  • Prognosis and Recurrence Monitoring

Sample Type

  • Blood
  • Urine
  • Saliva
  • Cerebrospinal Fluid
  • Others

Product

  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or System

Specimen

  • Blood
  • Bone Marrow
  • Other Body Fluids

End User

  • Research & Academic Institutes
  • Reference Laboratories
  • Hospitals
  • Physician Laboratories

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Regional Analysis/Insights

The circulating tumor cells (CTC) liquid biopsy market is analysed and market size insights and trends are provided, technology, application, clinical application, sample type, product, specimen and end user as referenced above.

The countries covered in the circulating tumor cells (CTC) liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates global circulating tumor cells (CTC) liquid biopsy market. This is majorly due to the growing adoption of the liquid biopsy in the North American region for diagnosis of cancer. There are rapidly growing cases of cancer in US which has contributed in the dominance of North America in the global liquid biopsy market.

Asia Pacific is expected to grow during the forecast period of 2023 to 2030. The major factors contributing for the growth of the market in include Asia Pacific the increasing disposable income, rising awareness regarding the liquid biopsy techniques, and rising adoption of the advanced techniques in the hospitals, clinics, diagnostic laboratories for the diagnosis and increasing healthcare expenditure. In addition, the increasing penetration of hospitals and diagnostic centers are further boosting the market’s growth in the Asia Pacific region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Share Analysis

The circulating tumor cells (CTC) liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to circulating tumor cells (CTC) liquid biopsy market.

Some of the major players operating in the circulating tumor cells (CTC) liquid biopsy market are:

  • QIAGEN (Germany)
  • Bio-Techne (U.S.)
  • Precision Medical Group, LLC. (U.S.)
  • Aviva Systems Biological Corporation (U.S.)
  • Biocept, Inc. (U.S.)
  • Fluxion Biosciences, Inc. (U.S.)
  • Greiner Bio-One International GmbH (Austria)
  • Ikonisys  (U.S.)
  • Miltenyi Biotec (Germany)
  • IVDiagnostics (U.S.)
  • BioFluidica (U.S.)
  • Canopus Medical (Sweden)
  • Biolidics Limited (Singapore)
  • Creativ MicroTech, Inc. (U.S.)
  • LungLife AI, Inc. (U.S.)
  • Epic Sciences (U.S.)
  • Rarecells Diagnostics (France)
  • ScreenCell (France)
  • Menarini Silicon Biosystems (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Circulating Tumor Cells (CTC) Liquid Biopsy Market is projected to grow at a CAGR of 17.17% during the forecast period by 2030.
The future market value of the Circulating Tumor Cells (CTC) Liquid Biopsy Market is expected to reach USD 4,170.06 million by 2030.
The major players in the Circulating Tumor Cells (CTC) Liquid Biopsy Market are QIAGEN (Germany), Bio-Techne (U.S.), Precision Medical Group, LLC. (U.S.), Aviva Systems Biological Corporation (U.S.), Biocept, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), Greiner Bio-One International GmbH (Austria) , etc.
The countries covered in the Circulating Tumor Cells (CTC) Liquid Biopsy Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials